IMCR – Immunocore Holdings plc ADR

Immunocore Holdings plc

IMCR

$31.86

Name : Immunocore Holdings plc

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $1,640,488,448.00

EPSttm : -0.64

Immunocore Holdings plc

$31.86

1.62%

$0.525

IMCR — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

15.3

Margin Of Safety %

Put/Call OI Ratio

0.27

EPS Next Q Diff

0.14

EPS Last/This Y

0.45

EPS This/Next Y

-0.73

Price

32.4

Target Price

60.82

Analyst Recom

1.69

Performance Q

-6.79

Upside

-124.9%

Beta

0.81

Ticker: IMCR

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-12	IMCR	29.05	1.19	2.73	20937
2026-10-13	IMCR	27.83	1.19	0.02	20983
2026-10-14	IMCR	28.35	1.32	0.00	20030
2026-10-15	IMCR	29.45	1.32	0.29	20036
2026-10-16	IMCR	29.42	1.32	0.24	20052
2026-10-19	IMCR	29.89	0.37	0.00	5094
2026-10-20	IMCR	32.64	0.33	0.00	5479
2026-10-21	IMCR	32.06	0.35	0.00	5242
2026-10-22	IMCR	32.16	0.27	0.00	6378
2026-10-23	IMCR	31.03	0.27	0.05	6405
2026-10-26	IMCR	31.31	0.27	0.00	6432
2026-10-27	IMCR	31.96	0.27	0.00	6432
2026-10-28	IMCR	32.68	0.27	0.20	6433
2026-10-29	IMCR	31.32	0.27	0.00	6437
2026-10-30	IMCR	30.44	0.27	2.89	6437
2026-11-02	IMCR	29.76	0.27	2.89	6437
2026-11-03	IMCR	29.98	0.27	2.89	6437
2026-11-04	IMCR	29.16	0.27	0.00	6458
2026-11-05	IMCR	28.44	0.27	0.50	6523
2026-11-06	IMCR	31.04	0.27	0.00	6533
2026-11-09	IMCR	31.79	0.27	0.00	6533
2026-11-10	IMCR	32.42	0.27	0.00	6572
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-12	IMCR	29.06	0.0	-	-0.04
2026-10-13	IMCR	27.81	0.0	-	-0.04
2026-10-14	IMCR	28.34	0.0	-	-0.04
2026-10-15	IMCR	29.41	0.0	-	-0.04
2026-10-16	IMCR	29.43	0.0	-	-0.04
2026-10-19	IMCR	29.90	0.0	-	-0.04
2026-10-20	IMCR	29.90	0.0	-	-0.04
2026-10-21	IMCR	32.64	0.0	-	-0.04
2026-10-22	IMCR	32.15	0.0	-	-0.04
2026-10-23	IMCR	30.99	0.0	-	-0.04
2026-10-26	IMCR	31.27	0.0	-	-0.04
2026-10-27	IMCR	31.97	0.0	-	-0.04
2026-10-28	IMCR	32.67	0.0	-	-0.04
2026-10-29	IMCR	31.31	0.0	-	-0.04
2026-10-30	IMCR	30.45	0.0	-	-0.04
2026-11-02	IMCR	29.78	0.0	-	-0.04
2026-11-03	IMCR	30.01	0.0	-	-0.05
2026-11-04	IMCR	29.21	0.0	-	-0.05
2026-11-05	IMCR	28.44	0.0	-	-0.05
2026-11-06	IMCR	31.05	0.0	-	-0.05
2026-11-09	IMCR	31.81	0.0	-	-0.05
2026-11-10	IMCR	32.40	0.0	-	-0.26
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-12	IMCR	0.00	-4.49	15.50
2026-10-13	IMCR	0.00	-4.49	15.50
2026-10-14	IMCR	0.00	-4.49	15.50
2026-10-15	IMCR	0.00	-4.49	15.50
2026-10-16	IMCR	0.00	-4.49	15.50
2026-10-19	IMCR	0.00	-4.53	15.50
2026-10-20	IMCR	0.00	-4.53	15.50
2026-10-21	IMCR	0.00	-4.53	15.50
2026-10-22	IMCR	0.00	-4.53	15.50
2026-10-23	IMCR	0.00	-4.53	15.50
2026-10-26	IMCR	0.00	-4.90	15.50
2026-10-27	IMCR	0.00	-4.90	15.30
2026-10-28	IMCR	0.00	-4.90	15.30
2026-10-29	IMCR	0.00	-4.90	15.30
2026-10-30	IMCR	0.00	-4.90	15.30
2026-11-02	IMCR	0.00	-4.86	15.30
2026-11-03	IMCR	0.00	-4.86	15.30
2026-11-05	IMCR	0.00	-4.86	15.30
2026-11-06	IMCR	0.00	-4.86	15.30
2026-11-09	IMCR	0.00	-5.09	15.30
2026-11-10	IMCR	0.00	-5.09	15.30
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.28

Avg. EPS Est. Current Quarter

-0.18

Avg. EPS Est. Next Quarter

-0.14

Insider Transactions

Institutional Transactions

-5.09

Beta

0.81

Average Sales Estimate Current Quarter

113

Average Sales Estimate Next Quarter

117

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

57.9

Max Drawdown 5-Year %

-67.4

Target Price

60.82

P/E

Forward P/E

PEG

P/S

3.89

P/B

4.01

P/Free Cash Flow

EPS

-0.62

Average EPS Est. Cur. Y

-0.26

EPS Next Y. (Est.)

-0.99

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-7.48

Relative Volume

1.77

Return on Equity vs Sector %

-33.9

Return on Equity vs Industry %

-14.2

EPS 1 7Days Diff

-0.2

EPS 1 30Days Diff

-0.21

EBIT Estimation

◆ IMCR Healthcare

$32.38

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

12/20

Pullback

8/25

Volume

3/15

Valuation

12/20

TP/AR

1/10

Options

6/10

RSI

57.4

Range 1M

78.7%

Sup Dist

4.7%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

4/25

Growth

11/30

Estimates

2/20

Inst/Vol

3/15

Options

8/10

EPS Yr

67.9%

EPS NY

-214.4%

52W%

36.1%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +87.8% upside

Quality

6/30

Valuation

16/30

Growth

6/25

Stability

5/10

LT Trend

2/5

Upside

+87.8%

Quality

IMCR — P/E HistoricalBiotechnology

Immunocore Holdings plc

Sector: Healthcare

Industry: Biotechnology

Employees: 524

Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

IMCR

Latest News

—

Caricamento notizie per IMCR…

stock quote shares IMCR – Immunocore Holdings plc ADR Stock Price stock today

news today IMCR – Immunocore Holdings plc ADR stock forecast ,stock prediction 2023 2024 2025

marketwatch IMCR – Immunocore Holdings plc ADR yahoo finance google finance

stock history IMCR – Immunocore Holdings plc ADR invest stock market

stock prices IMCR premarket after hours

ticker IMCR fair value insiders trading

IMCR – Immunocore Holdings plc ADR

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: IMCR

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y